Investigational drug · Phase 2
Descartes-08
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV).
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
7
Any phase or sponsor naming "Descartes-08"
First trial start
2019
Dec 4, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Descartes-08", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myasthenia Gravis, Generalized
- Childhood-onset Systemic Lupus Erythematous
- ANCA-Associated Vasculitis (AAV)
- Juvenile Myasthenia Gravis
- Juvenile Dermatomyositis
- Systemic Lupus Erythematosus (SLE)
- Antisynthetase Syndrome
Approved drugs for the same conditions: Myasthenia gravis · Lupus (SLE) · Neurology · Immunology and inflammation · Rare and genetic disease · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Descartes-08" as an intervention, largest first.
- Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisPivotal-lookingActive, not recruiting
Cartesian TherapeuticsIndustry
NCT06799247 · 128 participants · Start May 6, 2025 · Primary completion Dec 30, 2026
Drug: Decartes-08 · For: Myasthaenia Gravis
Sites: Tucson, Arizona; Carlsbad, California; Los Angeles, California · 34 sites in all
- Descartes-08 in Autoantibody MyositisRecruiting
Cartesian TherapeuticsIndustry
NCT07391605 · 60 participants (planned) · Start Apr 28, 2026 · Primary completion Nov 2027
Drug: Descartes-08 · For: Antisynthetase Syndrome
Sites: Orange, California; Boston, Massachusetts; Chapel Hill, North Carolina · 4 sites in all
Cartesian TherapeuticsIndustry
NCT07089121 · 50 participants (planned) · Start Jan 14, 2026 · Primary completion Dec 2027
Drug: Descartes-08 · For: Childhood-onset Systemic Lupus Erythematous; ANCA-Associated Vasculitis (AAV); Juvenile Myasthenia Gravis and 1 more
Sites: Washington D.C., District of Columbia; St Louis, Missouri; Cincinnati, Ohio
Cartesian TherapeuticsIndustry
NCT03448978 · 32 participants · Start Mar 8, 2018 · Primary completion Apr 19, 2021
Drug: Descartes-08; Fludarabine and 1 more · For: Multiple Myeloma
Sites: Bethesda, Maryland; Oklahoma City, Oklahoma; Fairfax, Virginia
- Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)Active, not recruiting
Cartesian TherapeuticsIndustry
NCT04146051 · 30 participants (planned) · Start Dec 4, 2019 · Primary completion Jan 5, 2026
Drug: Descartes-08 · For: Myasthenia Gravis, Generalized
Sites: Carlsbad, California; Irvine, California; Aurora, Colorado · 15 sites in all
Cartesian TherapeuticsIndustry
NCT04816526 · 13 participants · Start Dec 1, 2021 · Primary completion Aug 4, 2022
Drug: Descartes 08 · For: Myeloma Multiple
Sites: Orange, California; Nashville, Tennessee
- Descartes-08 for Patients With Systemic Lupus ErythematosusActive, not recruiting
Cartesian TherapeuticsIndustry
NCT06038474 · 6 participants · Start Feb 12, 2024 · Primary completion Dec 1, 2026
Drug: Descartes-08 · For: Systemic Lupus Erythematosus (SLE)
Sites: Oceanside, California
Newest research
PubMed records naming it or its code names, newest first.
- Descartes-08: Unlocking the potential of mRNA CAR T-cell therapy in myasthenia gravis.
Howard JF · Mol Ther 2026
- BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.
Fedak RR, Ruggerie RN, Shan Y, et al. · Nat Med 2026
- BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.
Vu T, Durmus H, Rivner M, et al. · Nat Med 2026
- Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis.
Chahin N, Sahagian G, Feinberg MH, et al. · Ann Clin Transl Neurol 2025
- Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
Granit V, Benatar M, Kurtoglu M, et al. · Lancet Neurol 2023
- Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Lin L, Cho SF, Xing L, et al. · Leukemia 2021
Also in development for Myasthenia Gravis, Generalized
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- PovetaciceptALPN-303Phase 37 trials
Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy
- ClaseprubartDNTH103Phase 34 trials
Dianthus Therapeutics · Myasthenia Gravis, Generalized, Chronic Inflammatory Demyelinating Polyneuropathy, Multifocal Motor Neuropathy
- AritinerceptPhase 21 trial
Aurinia Pharmaceuticals Inc. · Myasthenia Gravis, Generalized
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.